Canadian Health&Care; Mall

Administration of the treatments was double blind. Drug administration was at 8 am, and exercise bouts to angina were carried out at 9 am, 11 am, 1 pm, 2 pm, 4 pm, 6 pm, and at 7 pm. The patient then took his second daily dose of propranolol and went home. After the 9 am exercise, patients had a snack, and after the 2 pm test, patients ate lunch. By the end of each of the trial days, it was clear, based on the patient’s exercise performance during the day, whether the patient had received active nitroglycerin patch or placebo. On the day that the patient had received the nitroglycerin patch, he was invited to return to the lalxmitory the following morning for a single-blind test 24 hours after patch application. There was always at least a 10-day interval between trial days, and the study was completed within 8 to 12 days. During the whole period, except for the study days, patients took their usual dose of ISDN three times daily. Drug Company Involvement Ciba-Ceigy, Ltd, Basel, Switzerland, provided the 20 sq cm nitroglycerin patches (Nitroderm TTS, Transderm-Nitro) and identical-appearing placel>os. The study protocol was developed by the author who presented it to Ciba-Geigy, whereupon a research grant was made to facilitate performance of the study.